Resumen
Prostate cancer represents a substantial global health issue, and its intricacies continue to pose challenges for complete comprehension. In this study, an untargeted metabolomic and lipidomic approach was employed to analyze plasma samples obtained from patients diagnosed with benign prostatic hyperplasia (BPH), prostate cancer (PCa), and metastatic prostate cancer (Met). The results revealed significant changes in lipid metabolism when comparing patients with prostate cancer to those with benign prostatic hyperplasia and patients with metastasis. These findings support the fundamental importance of lipid metabolism in the development and progression of prostate cancer.